Remdesivir, tocilizumab helped patients: Study
Severely ill Covid-19 patients fared better when they received remdesivir and tocilizumab, two experimental drugs given individually or in combination, than those who did not get them, observed doctors from KEM Hospital, a premier medical college and hospital. (Source: The Economic Times)
Source: The Economic Times - July 3, 2021 Category: Consumer Health News Source Type: news

Government plans national stockpile of life-saving drugs to combat third Covid wave
The government is in discussions with the pharma and medical devices industry to create a "national stockpile" of life-saving drugs and vital equipment to combat the third Covid wave. This could prevent the massive shortages of critical drugs like Remdesivir, Tocilizumab, key antibiotics, and devices like oxygenators and pulse oximeters, as witnessed during the brutal second wave with a huge daily case-load. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 29, 2021 Category: Pharmaceuticals Source Type: news

Efficacy and Safety of Tocilizumab in Elderly GCA Patients Efficacy and Safety of Tocilizumab in Elderly GCA Patients
Tocilizumab has recently been approved for the treatment of giant cell arteritis, but what do we know about the safety and efficacy in elderly patients?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

FDA authorizes rheumatoid arthritis drug for emergency use to treat severely ill COVID-19 patients
Actemra, which is manufactured by Roche, will be given to hospitalized patients who are already receiving steroid drugs, oxygen and other measures to fight the virus. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2021 Category: Consumer Health News Source Type: news

Arthritis Drug Tocilizumb Gets FDA EUA for Severe COVID-19 Arthritis Drug Tocilizumb Gets FDA EUA for Severe COVID-19
For patients hospitalized with COVID-19, tocilizumab plus standard care has been shown to cut the risk for death, shorten hospitalization time, and reduce the need for mechanical ventilation.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 25, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Arthritis Drug Tocilizumab Gets FDA EUA for Severe COVID-19 Arthritis Drug Tocilizumab Gets FDA EUA for Severe COVID-19
For patients hospitalized with COVID-19, tocilizumab plus standard care has been shown to cut the risk for death, shorten hospitalization time, and reduce the need for mechanical ventilation.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). (Source: World Pharma News)
Source: World Pharma News - June 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVI...
Source: Roche Media News - June 25, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra ® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The E UA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVI...
Source: Roche Investor Update - June 25, 2021 Category: Pharmaceuticals Source Type: news

US approves Roche drug for emergency use against severe Covid-19
Though rising vaccinations in places such as Europe and the United States are reducing hospitalizations for COVID-19, Actemra is still being deployed for certain patients who land in the hospital. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 25, 2021 Category: Pharmaceuticals Source Type: news

CRP Level May Help Guide Use of Tocilizumab in COVID Pneumonia CRP Level May Help Guide Use of Tocilizumab in COVID Pneumonia
It's worth considering tocilizumab in patients with moderate-to-severe COVID-19-associated pneumonia and high CRP levels, according to follow-up data from a randomized controlled trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 26, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Arthritis drug can prevent COVID-19 deaths in the most serious patients, study finds 
Tocilizumab, a drug used to treat arthritis, may be effective in treating COVID-19 as well. Data shows that the drug can lead to better outcomes when used in high dosages. (Source: the Mail online | Health)
Source: the Mail online | Health - May 24, 2021 Category: Consumer Health News Source Type: news

Effectiveness of tocilizumab in patients hospitalized with COVID-19
(JAMA Network)What The Study Did:This follow-up study of a randomized clinical trial examines the association between survival and C-reactive protein levels in patients hospitalized with COVID-19 who were treated with tocilizumab. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 24, 2021 Category: Infectious Diseases Source Type: news

Covid-19: Key drugs, steroids in short supply; input costs surge
Two anti-virals — Remdesivir and Favipiravir — and Tocilizumab injections being used in the Covid-19 treatment have witnessed massive shortages over the last few months. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 21, 2021 Category: Pharmaceuticals Source Type: news

Delhi HC asks Centre to hold meeting with Roche to ensure immediate supply of Tocilizumab
Justice Prathiba M Singh said the officials of the ministry and the department shall hold a meeting with representatives of Roche India and its distributors here "to communicate and assess the demand for this drug in India". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 7, 2021 Category: Pharmaceuticals Source Type: news

Government in no rush to grant 'compulsory licences'
Amid suggestions to use the tool for Remdisivir and Tocilizumab, two drugs that are being used, government sources said that it made little sense to invoke compulsory licensing provisions, given that the active pharmaceutical ingredient (API) is not available in the country. (Source: The Economic Times)
Source: The Economic Times - May 7, 2021 Category: Consumer Health News Source Type: news

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
In patients with hypoxia and evidence of systemic inflammation (C-reactive protein ≥75 mg/L), the addition of tocilizumab to usual standard of care (82% receiving systemic corticosteroids) reduced 28-day mortality (31% v 35%; rate ratio 0.85; 95% CI 0.76–0.94; p=0.0028). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 4, 2021 Category: Consumer Health News Source Type: news

Vision Loss in Giant Cell Arteritis Treated With Tocilizumab Vision Loss in Giant Cell Arteritis Treated With Tocilizumab
A new study examines the incidence of vision loss among patients with giant cell arteritis during treatment with tocilizumab compared with conventional glucocorticoid therapy.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra ®
Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche's Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19 associated pneumonia. (Source: World Pharma News)
Source: World Pharma News - April 29, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Private hospitals to get remdesivir and tocilizumab through state governments
Private hospitals won ’t be able to procure remdesivir and tocilizumab required for Covid-19 treatment directly from manufacturers and will have to get them based on quotas set by state governments, which will, in turn, get them from the Centre. (Source: The Economic Times)
Source: The Economic Times - April 29, 2021 Category: Consumer Health News Source Type: news

RA Biologic's Serious Infection Risk Confounded by Order of Use RA Biologic's Serious Infection Risk Confounded by Order of Use
The risk for serious infection seen with tocilizumab is confounded by whether the drug is given as first-line or as subsequent treatment in the line of therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Govt makes interim allocation of COVID-19 treatment drug tocilizumab to states
In a letter, Pharma Joint Secretary Navdeep Rinwa and Health and Family Welfare Ministry Director Rajiv Wadhawan said the drug went out of stock in the country a few weeks ago due to a sudden surge in its demand because of a sharp rise in COVID-19 cases in the country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
Stabilization of lung function independent of the extent of quantitative radiographic interstitial lung disease or fibrosis at baseline (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 23, 2021 Category: Respiratory Medicine Tags: Dermatology, Pharmacy, Pulmonology, Radiology, Rheumatology, Journal, Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
FRIDAY, April 23, 2021 -- Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis (SSc), according to a study recently published in Arthritis& Rheumatology. David Roofeh, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news

Govt issues updated clinical guidance for management of COVID-19 patients
The guidelines issued by AIIMS, ICMR-COVID-19 National Task Force and the Joint Monitoring Group (DGHS) under the ministry stated that tocilizumab (a drug that modifies the immune system or its functioning) may be considered in patients with significantly raised inflammatory markers and not improving despite use of steroids with there being no active bacterial/fungal/tubercular infection. (Source: The Economic Times)
Source: The Economic Times - April 23, 2021 Category: Consumer Health News Source Type: news

The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials, International Immunopharmacology
Analysis (8 RCTs, n=6314) found tocilizumab does not provide a survival benefit for patients with COVID-19 (mortality at day 28 = 24.4% and 29.9% in tocilizumab and control groups, respectively), but it may help reduce the risk of mechanical ventilation and ICU admission. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 21, 2021 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 8th April 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together existing recommendations on managing COVID-19 so that healthcare staff and those planning and delivering services can find and use them more easily. The guideline includes new recommendations on therapeutics, and we will update the guideline further as new evidence emerges. 8 April 2021, Recommendations for using corticosteroids, tocilizumab and sarilumab to treat COVID-19 were added (including the evidence and rationale for making the recommendations). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news

Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report, Diagnostic microbiology and infectious disease
We present the case of a previously immunocompetent man with coronavirus disease-2019 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic ...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news

Arthritis Drug May Curb Myocardial Damage in Acute STEMI Arthritis Drug May Curb Myocardial Damage in Acute STEMI
Tocilizumab appears to improve myocardial salvage by helping tamp down the inflammatory overshoot that occurs during infarction and reperfusion.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 13, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Providing patient information leaflets following COVID-19 treatment, SPS
Following treatment for COVID-19 with tocilizumab, sarilumab or steroids, clinicians should provide suitable patient information leaflets at discharge. Forms attached to this page can be used by clinicians with patients to support the discharge process. The materials have been developed in conjunction with Dhivya Subramaniam, NHS England and NHS Improvement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 7, 2021 Category: Consumer Health News Source Type: news

Repurposing tocilizumab in scleroderma patients may prevent early lung disease
(Michigan Medicine - University of Michigan) A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Interleukin6 blocking agents for treating COVID19: a living systematic review, Cochrane Library
Authors'conclusions On average, tocilizumab reduces all ‐cause mortality at D28 compared to standard care alone or placebo and probably results in slightly fewer serious adverse events than standard care alone or placebo. Nevertheless, tocilizumab probably results in little or no increase in the outcome clinical improvement (defined as hospital dischar ge or improvement measured by trialist‐defined scales) at D28. The impact of tocilizumab on other outcomes is uncertain or very uncertain. With the data available, we were not able to explore heterogeneity. Individual patient data meta‐analyses are needed to be able to...
Source: Current Awareness Service for Health (CASH) - March 25, 2021 Category: Consumer Health News Source Type: news

Can medicines that block interleukin-6 (a protein involved in immune responses) treat COVID-19?
This recently published Cochrane review examines the effects of a class of treatments on people with COVID-19.  Treating COVID-19 with tocilizumab (a medicine that blocks interleukin-6) reduces the numbers of people who die within 28 days of treatment, and probably results in fewer serious unwanted effects than placebo treatment.Studies of other medicines that block interleukin-6 to treat COVID-19 are under way. The authors of this review will update this review when results from them become available.COVID-19COVID-19 is an infectious respiratory disease caused by a type of virus called a coronavirus. If the infection...
Source: Cochrane News and Events - March 18, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news

Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays
Swiss drugmaker Roche said on Thursday adding its drug Actemra to Gilead Sciences'Veklury medication, also called remdesivir, did not reduce hospital stays for patients with severe COVID-19 pneumonia.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 12, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 11, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 11, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Tocilizumab Use Not Supported for Moderate-to-Severe COVID-19
THURSDAY, March 11, 2021 -- Tocilizumab is not associated with progression of COVID-19 among adults admitted to hospital with moderate-to-severe COVID-19, according to a study published online March 4 in The Lancet Respiratory Medicine. Arvinder S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Media News)
Source: Roche Media News - March 11, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India — one of the world ’ s most ethnically diverse countries. (Source: University of Bristol news)
Source: University of Bristol news - March 8, 2021 Category: Universities & Medical Training Tags: Health, International, Publications, Research; Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
(University of Bristol) Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2021 Category: International Medicine & Public Health Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news

Does an Arthritis Drug Help Patients Battling Severe COVID? It Depends on the Study
WEDNESDAY, March 3, 2021 -- Two new studies suggest that the jury is still out on whether the arthritis drug tocilizumab helps those with severe COVID-19. Both reports were published recently in the New England Journal of Medicine. The first, from... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 3, 2021 Category: General Medicine Source Type: news

​IL - 6 Receptor Antagonists Benefit Critically Ill With COVID - 19 ​
Improved outcomes, including more organ support - free days, reduced mortality, seen with tocilizumab, sarilumab (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 2, 2021 Category: Respiratory Medicine Tags: Infections, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news

​IL-6 Receptor Antagonists Benefit Critically Ill With COVID-19​
TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ support in the intensive care unit (ICU), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 2, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia, New England Journal of Medicine
This placebo-controlled Phase III study of tocilizumab in patients hospitalised with severe Covid-19 pneumonia found no improvement in clinical status (primary endpoint; between-group difference -1.0; 95% CI -2.5 to 0; p=0.31) or mortality (19.7% v 19.4%; p=0.94) at day 28. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 1, 2021 Category: Consumer Health News Source Type: news